The Cyber Resilience Act forces a security reset for connected device makers

Tern plc

The EU Cyber Resilience Act introduces mandatory cybersecurity requirements for products with digital elements sold within the European Union, moving security obligations from guidance to enforceable regulation. For manufacturers of connected devices, embedded systems and industrial equipment, this represents a structural shift in how products must be designed, maintained and documented across their entire lifecycle.

The Act requires demonstrable security by design, secure default configurations, structured vulnerability handling and controlled software updates. Importantly, it also requires evidence. Companies must not only implement technical safeguards but also maintain documentation and processes that withstand regulatory scrutiny. This has implications for engineering resources, certification timelines and ongoing support costs.

Compliance is not a single event but an operational capability that must be embedded into product development and fleet management. Firms that delay implementation may face compressed delivery schedules, increased remediation costs or restricted market access. Those that prepare early can integrate compliance into standard operating processes and reduce disruption.

A central requirement of the Act is secure lifecycle management. Devices must be provisioned securely, authenticated reliably and updated safely throughout their operational life. Many legacy provisioning models rely on static credentials or manual processes that are difficult to scale and audit. Under the new framework, these approaches may expose companies to compliance gaps.

Device Authority positions its platform around automated device identity management, dynamic credential provisioning and policy enforcement. By embedding cryptographic identities into devices at scale and managing them throughout their lifecycle, manufacturers can create a structured control framework aligned with regulatory expectations. Automation reduces reliance on manual intervention and improves consistency across large device estates.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search